HRP20100521T1 - Monoklonska antitijela protiv čimbenika rasta hepatocita - Google Patents

Monoklonska antitijela protiv čimbenika rasta hepatocita Download PDF

Info

Publication number
HRP20100521T1
HRP20100521T1 HR20100521T HRP20100521T HRP20100521T1 HR P20100521 T1 HRP20100521 T1 HR P20100521T1 HR 20100521 T HR20100521 T HR 20100521T HR P20100521 T HRP20100521 T HR P20100521T HR P20100521 T1 HRP20100521 T1 HR P20100521T1
Authority
HR
Croatia
Prior art keywords
hgf
monoclonal antibody
mab
inhibits
binding
Prior art date
Application number
HR20100521T
Other languages
English (en)
Croatian (hr)
Inventor
Jin Kim Kyung
Su Yi-Chi
Original Assignee
Galaxy Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100521(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech filed Critical Galaxy Biotech
Publication of HRP20100521T1 publication Critical patent/HRP20100521T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HR20100521T 2004-04-15 2004-08-13 Monoklonska antitijela protiv čimbenika rasta hepatocita HRP20100521T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
HRP20100521T1 true HRP20100521T1 (hr) 2010-10-31

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100521T HRP20100521T1 (hr) 2004-04-15 2004-08-13 Monoklonska antitijela protiv čimbenika rasta hepatocita

Country Status (25)

Country Link
US (5) US20040208876A1 (de)
EP (2) EP1734995B1 (de)
JP (2) JP4594381B2 (de)
KR (1) KR101072736B1 (de)
CN (1) CN1964738A (de)
AT (1) ATE473760T1 (de)
AU (1) AU2004319276C1 (de)
BR (1) BRPI0418745A (de)
CA (1) CA2563080C (de)
CR (1) CR8698A (de)
CY (1) CY1110783T1 (de)
DE (1) DE602004028168D1 (de)
DK (1) DK1734995T3 (de)
ES (1) ES2346886T3 (de)
HR (1) HRP20100521T1 (de)
IL (1) IL178474A (de)
MX (1) MXPA06011822A (de)
NO (1) NO20065227L (de)
NZ (1) NZ550324A (de)
PL (1) PL1734995T3 (de)
PT (1) PT1734995E (de)
RU (1) RU2361879C2 (de)
SI (1) SI1734995T1 (de)
WO (1) WO2005107800A1 (de)
ZA (1) ZA200609407B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR101254371B1 (ko) * 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
EP1773885B1 (de) * 2004-08-05 2010-04-21 Genentech, Inc. Humanisierte anti-cmet-antagonisten
EP1885400A4 (de) * 2005-06-02 2011-01-26 Galaxy Biotech Llc Verfahren zur behandlung von hirntumoren durch antikörper
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) * 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
CA2637917C (en) 2006-01-27 2015-11-24 Keio University Therapeutic agents for diseases involving choroidal neovascularization
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2025346B1 (de) 2006-04-07 2016-08-10 Osaka University Mittel zur förderung der muskelregeneration
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
WO2008090901A1 (ja) 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
EP2170268A2 (de) * 2007-06-25 2010-04-07 Amgen, Inc. Zusammensetzungen von spezifischen bindungsmitteln für den hepatozyten-wachstumsfaktor
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
EP2288383A1 (de) * 2008-05-14 2011-03-02 Amgen, Inc Kombinationen von vegf(r)-inhibitoren und hepatozyten-wachstumsfaktor (c-met)-inhibitoren zur behandlung von krebs
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (de) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET-Antikörper und seine Verwendung zur Erkennung und Diagnose von Krebs
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2621483A1 (de) 2010-09-27 2013-08-07 Exelixis, Inc. Met- und vegf-doppelinhibitoren zur behandlung von kastrationsresistentem prostatakrebs und osteoblastischen knochenmetastasen
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
CZ2011514A3 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
CN103974720A (zh) 2011-09-09 2014-08-06 安姆根有限公司 C-met蛋白质用于预测抗肝细胞生长因子(“hgf”)抗体在食管癌和胃癌患者中的功效的用途
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
EP2873422A4 (de) 2012-07-10 2015-12-30 Takeda Pharmaceutical Pharmazeutische zubereitung zur injektion
EP2708556B1 (de) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmazeutische zusammensetzung zur verwendung in einer kombinationstherapie zur prävention oder behandlung von c-met- oder angiogenesefaktorinduzierten erkrankungen
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
EP3698808B1 (de) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
CN121358764A (zh) * 2023-05-05 2026-01-16 布坦坦研究所 人抗FGF2单克隆抗体(mAb)、包含其的药物组合物、其用途和用于检测包含所述mAb的生物样品中的癌症的试剂盒

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (de) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9110202D0 (en) * 1991-05-10 1991-07-03 Erba Carlo Spa Truncated forms of the hepatocyte growth factor(hgf)receptor
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
IL127558A0 (en) * 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
EP1423432A4 (de) 2001-07-26 2006-01-11 Lilly Co Eli Interleukin-1-beta-antikörper
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
MXPA05013181A (es) 2003-06-06 2006-06-23 Genentech Inc Metodos y composiciones para modular hgf/met.
DE602004024536D1 (de) 2003-07-07 2010-01-21 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
KR101254371B1 (ko) * 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
EP1885400A4 (de) 2005-06-02 2011-01-26 Galaxy Biotech Llc Verfahren zur behandlung von hirntumoren durch antikörper
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
HK1094167A1 (en) 2007-03-23
MXPA06011822A (es) 2007-03-23
IL178474A0 (en) 2007-02-11
NZ550324A (en) 2009-12-24
SI1734995T1 (sl) 2010-09-30
CN1964738A (zh) 2007-05-16
AU2004319276C1 (en) 2011-03-03
KR101072736B1 (ko) 2011-10-11
EP1734995A4 (de) 2007-04-25
US20070160613A1 (en) 2007-07-12
US20120064066A1 (en) 2012-03-15
PT1734995E (pt) 2010-08-18
EP1734995A1 (de) 2006-12-27
EP2204191A1 (de) 2010-07-07
AU2004319276B2 (en) 2010-08-26
AU2004319276A1 (en) 2005-11-17
JP4594381B2 (ja) 2010-12-08
DE602004028168D1 (de) 2010-08-26
ES2346886T3 (es) 2010-10-21
US7687063B2 (en) 2010-03-30
CY1110783T1 (el) 2015-06-10
IL178474A (en) 2011-04-28
CA2563080A1 (en) 2005-11-17
BRPI0418745A (pt) 2007-12-11
ZA200609407B (en) 2008-07-30
WO2005107800A1 (en) 2005-11-17
US20080019966A1 (en) 2008-01-24
CR8698A (es) 2007-12-17
EP1734995B1 (de) 2010-07-14
RU2361879C2 (ru) 2009-07-20
CA2563080C (en) 2015-01-27
RU2006140257A (ru) 2008-05-20
US7494650B2 (en) 2009-02-24
JP2007532643A (ja) 2007-11-15
NO20065227L (no) 2007-01-10
US20040208876A1 (en) 2004-10-21
JP2011012067A (ja) 2011-01-20
DK1734995T3 (da) 2010-10-25
KR20070012711A (ko) 2007-01-26
ATE473760T1 (de) 2010-07-15
PL1734995T3 (pl) 2010-12-31
US20090104192A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
HRP20100521T1 (hr) Monoklonska antitijela protiv čimbenika rasta hepatocita
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
HRP20191609T1 (hr) Protein
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
HK1221153A1 (zh) 抗体-药物缀合物
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
JP2017512765A5 (de)
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
JP2018534933A5 (de)
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP2020522280A5 (de)
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
JP2020522281A5 (de)
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
MXPA06003788A (es) Anticuerpos completamente humanos contra 4-1bb humano (cd137).
CY1115456T1 (el) Μεθοδος χορηγησης αντισωματων αντι-ιl-5
RU2006132466A (ru) Высококонцентрированные жидкие композиции анти-egfr антител
CA2952113A1 (en) Anti-axl antibodies
JP2018529635A5 (de)
JP2020533965A5 (de)
AR046094A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer